Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook

May 1, 2012 7:41 AM EDT Send to a Friend
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q1 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $691 million versus the consensus estimate of $700.34 million.

Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment